The identification of the various nicotinic receptor subtypes, when coupled with the recent development of three-dimensional structures of surrogate extracellular receptor domains, offers new opportunities to design nicotinic ligands. Conformation and fluctuations in receptor structure are critical to ligand selectivity, and we present here how a flexible receptor template can be used in the development of selective ligands affecting cholinergic neurotransmission.Close to a century ago Langley and his student Elliot proposed that cellular communication within the nervous system occurred through chemical neurotransmission. A necessary corollary of their proposal is the existence of receptors, termed by them as 'receptive substances'. 1 For the first 70 years, receptors were studied by inference through structureactivity relationships, enantiomeric selectivity, agonist-antagonist relationships and, somewhat later, covalent modifications to influence responsiveness. Only in the last 30 years, with the discovery of α-bungarotoxin to identify and characterize the nicotinic acetylcholine receptor, 2 have we witnessed the treatment of the receptor as a discrete chemical entity. A century following Langley's studies in this genome-based era a new paradigm has emerged, where a structural template or surrogate structure does or will soon exist for all receptors and biological targets.Sequencing the genome yielded a potential primary structure for all of the targets of drug action, and technical advances in crystallography and NMR spectrometry have produced structures of the gene products or individual domains of gene products at atomic level resolution. In some cases the actual receptor target has been characterized structurally; 3 in others, a homologous surrogate target has a resolved structure. 4-6 Accordingly, these structures, similar to lead compounds in small molecule design, provide templates for drug discovery. However, sequence differences between members of homologous proteins, structural constraints imposed by the crystallization process and the recognition that the ligand itself may induce changes in structure are considerations that require continuous refinement of the template.An appropriate example comes from considerations of the nicotinic acetylcholine receptor (nAChR), where a recently crystallized homopentameric acetylcholine binding protein (AChBP) isolated from the fresh water snail Lymnaea, was shown to be homologous to the N-terminal 210 amino acids in the nAChR. 5,7 As a soluble entity homologous to the extracellular domain of the receptor, but lacking in its transmembrane spans, the protein can be purified and crystallized. We have synthesized the encoding gene and expressed this protein from Lymnaea as well as from the saltwater species, Aplysia. 8,9 The sequences and